Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Markman Shares Hopes for 2024, Underscoring Need for Meaningful Decision Support Across Oncology

December 28th 2023

Maurie Markman, MD, discusses current challenges faced with developing robust decision support tools for oncologists and projects additional research efforts dedicated to finding a way to leverage CAR T-cell therapies in solid tumors to improve patient outcomes.

Markman Reflects on Key Advances Made in 2023 in the Realm of Gynecologic Cancers and Beyond

December 27th 2023

Maurie Markman, MD, highlights inroads made with immunotherapy, antibody-dependent cytotoxic agents, and molecular testing across oncology.

Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer

December 27th 2023

Leslie M. Randall, MD, reviews updates to the NCCN guidelines for cervical cancer, including the use of pembrolizumab in the second and third-line settings, the results of the KEYNOTE-826 trial, and the potential role of induction chemotherapy with weekly carboplatin and paclitaxel in the treatment of locally advanced cervical cancer.

Staging and Biomarker Testing For Patients With Cervical Cancer

December 27th 2023

David M. O’Malley, MD, discusses cervical cancer epidemiology, risk factors, and diagnosis, highlighting the importance of HPV vaccinations, regular PAP smears, and the use of various biomarkers for treatment decision making.

Clinical Pearls for Community Oncologists Treating Patients With Advanced Endometrial Cancer

December 26th 2023

Floor Backes, MD, closes the discussion by explaining that endometrial cancer care is rapidly evolving and complicated, requiring calling on colleagues for guidance, getting molecular profiling, and encouraging trial participation.

Unmet Needs in the Management of Patients With Advanced Endometrial Cancer

December 26th 2023

Looking ahead, Floor Backes, MD, notes that key needs in the treatment of advanced endometrial cancer are figuring out next steps when immunotherapy resistance develops, targeted radiation for oligometastatic disease, and sorting patients into subgroups for personalize care.

What Fellows Need to Know: Key Takeaways From ESMO 2023

December 26th 2023

The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.

Being Part of the Contagious Enthusiasm

December 24th 2023

In a full-circle scenario, Cedars-Sinai Cancer, based in Los Angeles, California, welcomed back Margaret Liang, MD, MSHPM, in July 2023 to the institution where she completed her fellowship.

Gynecologic Oncologists Highlight Ongoing Areas of Exploration Throughout the Treatment Armamentarium

December 22nd 2023

Michael P. Stany, MD, discusses the optimization of PARP inhibitors in the upfront maintenance setting of ovarian cancer, the benefit of novel targets and immunotherapy combinations, and the role of immunotherapy in the treatment of advanced endometrial cancer.

FDA Grants Breakthrough Therapy Designation to BNT323/DB-1303 in Endometrial Cancer

December 21st 2023

The FDA has granted breakthrough therapy designation to the HER2-targeted antibody-drug conjugate BNT323/DB-1303 for use as a potential therapeutic option in patients with advanced endometrial cancer who have progressed on or after treatment with immune checkpoint inhibitors.

Dostarlimab Plus Chemo Followed by Dostarlimab/Niraparib Improves PFS in Endometrial Cancer

December 20th 2023

Dostarlimab plus carboplatin and paclitaxel, followed by maintenance dostarlimab and niraparib, significantly improved PFS vs placebo plus chemotherapy followed by placebo in patients with primary advanced or recurrent endometrial cancer, according to data from the phase 3 RUBY trial.

Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer

December 20th 2023

Experts are enthusiastic about the potential of antibody drug conjugates to de-escalate therapy and reduce toxicity in advanced and recurrent endometrial cancer treatment, with a focus on the importance of diversity plans in clinical trials to ensure broader applicability.

Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer

December 20th 2023

The panel highlights recent data on antibody drug conjugates targeting TROP2 in patients with advanced or recurrent endometrial cancer and the need for dose optimization.

Individual Disease Histology and Local Control Are Key Considerations in Endometrial Cancer Care

December 18th 2023

Hope Cottrill, MD, highlights practice-changing developments in endometrial cancer care, the benefits of local control with radiation in patients with locally aggressive disease, and questions that remain regarding treatment sequencing with immunotherapy.

The TROPiCS-03 Study: Sacituzumab Govitecan in Patients With Advanced Endometrial Cancer

December 18th 2023

Floor Backes, MD, and Matthew Powell, MD, review data on sacituzumab govitecan, an antibody-drug conjugate targeting topoisomerase in patients with advanced endometrial cancer.

Adverse Events Seen With Systemic Therapies in Patients With Advanced Endometrial Cancer

December 18th 2023

Drs Backes and Powell discuss the management of adverse events between upfront immunotherapy versus chemotherapy followed by later immunotherapy for endometrial cancer, noting the need for molecular subgroup data from trials like LEAP-001.

Pembrolizumab Plus Lenvatinib Misses Both Survival End Points in Advanced, Recurrent Endometrial Cancer

December 15th 2023

The combination of pembrolizumab and lenvatinib failed to produce a statistically significant improvement in progression-free survival and overall survival vs platinum-based chemotherapy with carboplatin and paclitaxel as frontline therapy in patients with advanced or recurrent endometrial cancer whose disease in mismatch repair proficient/not microsatellite instability–high or mismatch repair deficient.

Dostarlimab Plus Chemo Granted EU Approval for dMMR/MSI-H Endometrial Cancer

December 14th 2023

The European Commission has granted marketing authorization to dostarlimab paired with carboplatin and paclitaxel in adults with dMMR/MSI-H primary advanced or recurrent endometrial cancer who are eligible to receive systemic treatment.

Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer

December 13th 2023

Key opinion leaders share excitement about antibody-drug conjugates targeting HER2 in advanced or recurrent endometrial cancer, and debate optimal HER2 testing methods, with some preferring gastric cancer scoring criteria over breast cancer criteria.

Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer

December 13th 2023

The panel reviews results from the ATTEND and DUO-E trials in advanced endometrial cancer, suggesting pembrolizumab remains the standard for the dMMR patient subset while combinations with PARP inhibitors may improve outcomes in pMMR.